The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Regulatory News (ZTF)

Share Price Information for Zotefoams (ZTF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 524.00
Bid: 524.00
Ask: 530.00
Change: 4.00 (0.77%)
Spread: 6.00 (1.145%)
Open: 524.00
High: 532.00
Low: 520.00
Prev. Close: 520.00
ZTF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Chair Succession

24 May 2023 07:00

RNS Number : 4142A
Zotefoams PLC
24 May 2023
 

Zotefoams plc

("Zotefoams" or "Group")

 

Trading Update and Chair Succession

 

24 May 2023 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the four months ended 30 April 2023, ahead of its Annual General Meeting to be held today at 10am at 675 Mitcham Road, Croydon, CR9 3AL.

At this meeting Steve Good, Chair of Zotefoams, will make the following statement:

Trading in the four months ended 30 April 2023 was strong, with the Group delivering continued year-on-year revenue growth and with margins benefiting from pricing, operational efficiency initiatives and a stronger US dollar. In addition, levels of input cost inflation were lower in the period and the Group has also benefitted from the phasing of planned SG&A spend increases.

Highlights, against the comparative prior year period, were:

Group sales increased by 15%

Polyolefin Foams sales increased by 14%:

- Volumes declined by 5%, primarily due to market-specific factors in continental Europe, which was more than offset by higher average selling prices as a result of previously implemented increases, favourable exchange rates and product mix

High-Performance Products (HPP) sales increased by 19%:

- Footwear sales grew strongly, with a 12% increase in volumes and a higher average selling price, primarily due to the stronger US dollar but also with a slightly more favourable product mix

- Sales volumes of ZOTEK® F technical foams for aviation and other markets declined by 13%. A relatively slow start to the year belies an improved demand environment

- T-FIT® insulation products sales were at a similar level

- In line with the normal seasonality of our business, our HPP business represents a smaller share of total revenue at this stage in the year

MuCell Extrusion's focus is on the technical and commercial development of ReZorce® mono-material packaging solutions. In the period, the business unit has:

- Transitioned its initial raw material formulations to its facility in Denmark in preparation for commercial trials in Europe for ReZorce cartons

- Made good progress on downstream processing of ReZorce sheet for cartons using off-the shelf commercial processing equipment

Cash generation and management has been strong in the period, with the leverage ratio being around 1.1x on a trailing 12-month basis, improved from 1.2x at 31 December 2022.

 

While the macroeconomic environment remains uncertain, the cost environment for the Group has improved in the early part of 2023.

Pricing for LDPE (the main material used in polyolefin foams) is relatively stable and at levels which are significantly lower than the all-time highs seen in 2022, albeit higher than long-term historic average pricing. Energy costs have also fallen from recent highs, but market prices remain volatile and forward prices are significantly higher than spot price as a result. Other cost inflation has generally been moderate with the exception of speciality polymers and wage inflation.

In the previous two years, Zotefoams has reacted to input-price movements by increasing selling prices and focusing on internal efficiencies and controllable costs, while proactively implementing actions to mitigate supply chain risks. In the period, there have been no major pricing actions and the current focus in Polyolefin Foams is to align the Group's product offering and pricing with the value its products deliver across markets globally.

Outlook

The Board anticipates further sales growth in the year to come primarily from the HPP portfolio, with good opportunities across all product groups. Prospects for volume growth in the Polyolefin Foams business unit are more reliant on general industrial market conditions, which we expect to remain challenging everywhere except for North America. At current exchange rates, the Board expects little impact from currency on full-year profit.

Internally, the Group is well-positioned to deliver further operational improvements and its spending plans are focused on key deliverables. This includes a significant spend on the ReZorce mono-material packaging development within the MuCell Extrusion business unit.

Performance in the early part of the year evidences continued demand for the Group's products together with its resilient operating platform. While being mindful of remaining macroeconomic volatility, the Board's full year expectations remain unchanged and it is confident about the long-term prospects of the business.

Chair Succession

As previously announced, Steve Good, who has been Chair of Zotefoams plc since 2016 and a non-executive director since 2014, will step down from the Board following the conclusion of the 2023 AGM. Steve will be replaced as Chair by Dr Lynn Drummond.

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"I am pleased with the business performance in the first four months of the year and also the progress made on ReZorce carton development. The business has opportunities for growth in a number of HPP markets and better margins in Polyolefin Foams reflect pricing and cost management actions taken over the past year. With good cash generation and management, the business is well placed for further growth.

"It has been a pleasure to work with Steve Good as a fellow Director since 2014 and Chair since 2016, over which time the business has experienced strong growth and transformational change, which has included significant investment in global manufacturing capacity and in new product development. On behalf of the Board of Zotefoams plc and our management and staff, I thank Steve for his contribution to our success over the years and wish him all the best for the future." 

 

Note. The Board understands that current market expectations for the year ended 31 December 2023 are revenue of £135m and adjusted profit before tax of £12.6m.

 

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

IFC Advisory (Financial PR & IR)

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE®polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA and Stilling, Denmark (microcellular foam technology) and Jiangsu Province, China (T-FIT).

www.zotefoams.com

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPPURUAUPWGMW
Date   Source Headline
13th Sep 20223:43 pmRNSDirector/PDMR Shareholding
23rd Aug 20224:35 pmRNSPrice Monitoring Extension
22nd Aug 20224:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20224:36 pmRNSPrice Monitoring Extension
12th Aug 20221:43 pmRNSDirector/PDMR Shareholding
11th Aug 20223:50 pmRNSHolding(s) in Company
9th Aug 20227:00 amRNSInterim Results
2nd Aug 20224:35 pmRNSPrice Monitoring Extension
20th Jul 20224:42 pmRNSSecond Price Monitoring Extn
20th Jul 20224:36 pmRNSPrice Monitoring Extension
12th Jul 202212:39 pmRNSDirector/PDMR Shareholding
8th Jul 20227:00 amRNSNotice of Results
30th Jun 20224:52 pmRNSDirector/PDMR Shareholding
8th Jun 20224:40 pmRNSSecond Price Monitoring Extn
8th Jun 20224:35 pmRNSPrice Monitoring Extension
8th Jun 20228:49 amRNSDirector/PDMR Shareholding
26th May 20224:41 pmRNSSecond Price Monitoring Extn
26th May 20224:36 pmRNSPrice Monitoring Extension
25th May 20221:04 pmRNSResult of the 2022 Annual General Meeting
25th May 20227:00 amRNSTrading Update
18th May 20224:41 pmRNSSecond Price Monitoring Extn
18th May 20224:36 pmRNSPrice Monitoring Extension
12th May 20223:58 pmRNSDirector/PDMR Shareholding
11th May 20222:13 pmRNSDirector/PDMR Shareholding
25th Apr 20225:16 pmRNSDirector/PDMR Shareholding
25th Apr 20227:00 amRNS2021 Annual Report and Notice of the 2022 AGM
11th Apr 20223:49 pmRNSDirector/PDMR Shareholding
22nd Mar 20227:00 amRNSPreliminary Results
14th Mar 202212:30 pmRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSNotice of results and investor presentation
15th Feb 20224:26 pmRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSFull Year Trading Update
12th Jan 202211:12 amRNSDirector/PDMR Shareholding
23rd Dec 20211:56 pmRNSDirector/PDMR Shareholding
17th Dec 20217:00 amRNSTrading Update
14th Dec 202111:55 amRNSDirector/PDMR Shareholding
12th Nov 202112:41 pmRNSDirector/PDMR Shareholding
10th Nov 20215:48 pmRNSHolding(s) in Company
4th Nov 20215:59 pmRNSHolding(s) in Company
4th Nov 20213:31 pmRNSDirector/PDMR Shareholding
3rd Nov 20217:00 amRNSQ3 Trading Update
15th Oct 202112:10 pmRNSDirector/PDMR Shareholding
12th Oct 202111:05 amRNSDirector/PDMR Shareholding
1st Oct 20213:31 pmRNSHolding(s) in Company
14th Sep 202110:05 amRNSDirector/PDMR Shareholding
12th Aug 20212:28 pmRNSDirector/PDMR Shareholding
10th Aug 20217:00 amRNSInterim Results
19th Jul 20219:26 amRNSNotice of Results
13th Jul 20211:59 pmRNSDirector/PDMR Shareholding
14th Jun 20213:06 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.